Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor.
Ontology highlight
ABSTRACT: OPINION STATEMENT: Inflammatory myofibroblastic tumor (IMT), characterized by intermediate malignancy and a propensity for recurrence, has presented a formidable clinical challenge in diagnosis and treatment. Its pathological characteristics may resemble other neoplasms or reactive lesions, and the treatment was limited, taking chemotherapies as the only option for those inoperable. However, discovering anaplastic lymphoma kinase (ALK) protein expression in approximately 50% of IMT cases has shed light on a new diagnostic approach and application of targeted therapies. With the previous success of combating ALK+ non-small-cell lung cancers with ALK tyrosine kinase inhibitors (TKIs), crizotinib, a first-generation ALK-TKI, was officially approved by the U.S. Food and Drug Adminis
SUBMITTER: Wang QA
PROVIDER: S-EPMC10781869 | biostudies-literature | 2023 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA